$11.91
▲ +0.7% Today
as of Jul 22, 16:54 ET
Last 30 days
Recent Press Releases & News
Silence Therapeutics plc (SLN) Initiated at Overweight as Analyst Highlights siRNA Pipeline Potential
Silence Therapeutics (SLN) Surges 26.0%: Is This an Indication of Further Gains?
How Silence Therapeutics (SLN) Is Building the Divesiran Case Around Fewer Blood Draws in Polycythemia Vera
Overview
52-week range
$4.19
$8.40
100% of range
Avg surprise (last 3)
-110.1%
Avg reaction (last 2)
-4.7%
0% positive
Latest IV / EM
309%
EM ±70.8% · $13 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 7, 2026 | Mar/2026 | $-0.32 | $-0.33 | +3.0% | +46.7% | -5.6% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.15 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $-0.54 | $-0.27 | -100.0% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $-0.60 | $-0.18 | -233.3% | — | -3.8% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.25 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.14 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.02 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 6, 2026 | Jun/2026 | OTHER | -$0.32 | -$0.54 | +40.7% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $422,000 | — | $159,000 | $224,000 | $142,000 | — | $1M | $756,000 |
| Cost of revenue | $11,000 | — | $64,000 | $85,000 | $54,000 | — | $4M | $3M |
| Gross profit | $411,000 | — | $95,000 | $139,000 | $88,000 | — | $-2M | $-3M |
| Operating income | $-16M | — | $-26M | $-24M | $-28M | — | $-30M | $-23M |
| Net income | $-15M | — | $-21M | $-27M | $-29M | — | $-36M | $-20M |
| EPS (diluted) | $-0.11 | — | $-0.15 | $-0.19 | $-0.20 | — | $-0.25 | $-0.14 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $6M | $11M | $82M | $42M | $65M | $121M | — | — |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $103M | $119M | $134M | $149M | $170M | $187M | — | — |
| Total assets | $115M | $131M | $147M | $165M | $185M | $203M | — | — |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $66M | $69M | $73M | $71M | $73M | $69M | — | — |
| Total equity | $49M | $62M | $74M | $94M | $113M | $134M | $127M | $143M |